Disease · HP_0010992
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Gefapixant vs Placebo: deaths from any cause | 0 of 186 | 0 of 190 | 376 | NCT04193176 | Trial comparisons |
| Gefapixant vs Placebo: serious adverse events | 3 of 185 | 2 of 190 | 375 | NCT04193176 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary | 103 of 198 | 52 of 97 | 295 | NCT01893138 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months | 53 of 198 | 22 of 97 | 295 | NCT01893138 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months | 73 of 198 | 30 of 97 | 295 | NCT01893138 | Trial comparisons |
| Botox A vs Mid-Urethral Sling: deaths from any cause | 0 of 71 | 0 of 69 | 140 | NCT04171531 | Trial comparisons |
| Botox A vs Mid-Urethral Sling: serious adverse events | 3 of 71 | 8 of 69 | 140 | NCT04171531 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months (Prior Surgery Participants Only) | 20 of 50 | 4 of 25 | 75 | NCT01893138 | Trial comparisons |
| Iltamiocel vs Placebo: Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months (Prior Surgery Participants Only) | 14 of 50 | 3 of 25 | 75 | NCT01893138 | Trial comparisons |
| Imipramine vs Placebo: deaths from any cause | 0 of 16 | 0 of 16 | 32 | NCT03102645 | Trial comparisons |
| Imipramine vs Placebo: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT03102645 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/HP_0010992/comparisons